[go: up one dir, main page]

WO2002020509A3 - Arzneimittel gegen virale erkrankungen - Google Patents

Arzneimittel gegen virale erkrankungen Download PDF

Info

Publication number
WO2002020509A3
WO2002020509A3 PCT/EP2001/009772 EP0109772W WO0220509A3 WO 2002020509 A3 WO2002020509 A3 WO 2002020509A3 EP 0109772 W EP0109772 W EP 0109772W WO 0220509 A3 WO0220509 A3 WO 0220509A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
viral infections
against viral
medicaments against
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/009772
Other languages
English (en)
French (fr)
Other versions
WO2002020509A2 (de
Inventor
Susanne Nikolic
Stephan Bartel
Michael Brands
Ulrich Niewoehner
Arnold Paessens
Erwin Graef
Karl-Heinz Schlemmer
Kerstin Henninger
Rainer Endermann
Olaf Weber
Diana Koletzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000143791 external-priority patent/DE10043791A1/de
Priority claimed from DE2000154932 external-priority patent/DE10054932A1/de
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU2001289831A priority Critical patent/AU2001289831A1/en
Publication of WO2002020509A2 publication Critical patent/WO2002020509A2/de
Publication of WO2002020509A3 publication Critical patent/WO2002020509A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Chromanonderivate sind hochwirksame antivirale Mittel. Kombinationen von Chromanonen und/oder Chromanolen mit HBV-Polymerase-Inhibitoren, HBV-DNA- bzw. HBV-core-Protein-Inhibitoren und/oder Isoxazolen und gegebenenfalls Interferon hemmen die Vermehrung von HBV-Viren besser als bislang bekannte Mittel.
PCT/EP2001/009772 2000-09-06 2001-08-24 Arzneimittel gegen virale erkrankungen Ceased WO2002020509A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289831A AU2001289831A1 (en) 2000-09-06 2001-08-24 Medicaments against viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2000143791 DE10043791A1 (de) 2000-09-06 2000-09-06 Arzneimittel gegen virale Erkrankungen
DE10043791.5 2000-09-06
DE10054932.2 2000-11-06
DE2000154932 DE10054932A1 (de) 2000-11-06 2000-11-06 Arzneimittelkombinationen gegen virale Erkrankungen

Publications (2)

Publication Number Publication Date
WO2002020509A2 WO2002020509A2 (de) 2002-03-14
WO2002020509A3 true WO2002020509A3 (de) 2002-06-27

Family

ID=26006936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009772 Ceased WO2002020509A2 (de) 2000-09-06 2001-08-24 Arzneimittel gegen virale erkrankungen

Country Status (3)

Country Link
US (1) US20020082264A1 (de)
AU (1) AU2001289831A1 (de)
WO (1) WO2002020509A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093389B2 (en) 2007-01-12 2012-01-10 Merck Sharp & Dohme Corp. Substituted spirochromanone derivatives

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796086A (zh) * 2006-04-18 2012-11-28 雅培制药有限公司 香草素受体亚型1(vr1)的拮抗剂及其用途
RS20090249A (sr) * 2006-11-29 2010-06-30 Pfizer Products Inc. Spiroketon inhibitori acetil-coa karboksilaze
WO2008088692A2 (en) * 2007-01-12 2008-07-24 Merck & Co., Inc. Spirochromanon derivatives
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
CN102558126B (zh) * 2010-12-16 2014-03-05 复旦大学 2-取代色原酮类化合物及其制备方法和用途
SG192248A1 (en) 2011-02-02 2013-09-30 Vertex Pharma Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
AU2015242219A1 (en) 2014-03-29 2016-10-06 Lupin Limited Sulfonamide compounds as Voltage gated sodium channel modulators
CN104262317B (zh) * 2014-09-04 2016-08-17 玉溪师范学院 一种二聚单萜类化合物及其制备方法与应用
CN107311973B (zh) * 2017-06-25 2021-04-06 石家庄学院 一种含硝酸酯基二氢杨梅素衍生物及其制备和应用
WO2025015178A1 (en) * 2023-07-11 2025-01-16 Pretzel Therapeutics, Inc. Modulators of mitochondrial dna replication

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611910A1 (de) * 1976-03-20 1977-09-22 Bayer Ag Chromanone-(4)
EP0004624A2 (de) * 1978-04-07 1979-10-17 Bayer Ag Neue Chromanon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel und Wachstumsförderer
WO1995030642A1 (en) * 1994-05-06 1995-11-16 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
EP0695547A1 (de) * 1993-04-09 1996-02-07 Toyama Chemical Co., Ltd. Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US6046355A (en) * 1996-11-01 2000-04-04 Warner-Lambert Company Dihydropyrones with improved antiviral activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611910A1 (de) * 1976-03-20 1977-09-22 Bayer Ag Chromanone-(4)
EP0004624A2 (de) * 1978-04-07 1979-10-17 Bayer Ag Neue Chromanon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel und Wachstumsförderer
EP0695547A1 (de) * 1993-04-09 1996-02-07 Toyama Chemical Co., Ltd. Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
WO1995030642A1 (en) * 1994-05-06 1995-11-16 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US6046355A (en) * 1996-11-01 2000-04-04 Warner-Lambert Company Dihydropyrones with improved antiviral activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIN-TENG CHANG ET AL.: "Coumarins and Anti-HBV constizuents from Zanthoxylum Schinifolium", PHYTOCHEMISTRY., vol. 45, no. 7, 1997, PERGAMON PRESS., GB, pages 1419 - 1422, XP004293278, ISSN: 0031-9422 *
STEVE R. TURNER ET AL.: "Tipranavir(PNU-140690) A potent, Orally Bioavailable Nonpeptidic HIV protease inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class", JOURNAL OF MEDICINAL CHEMISTRY., vol. 41, no. 18, 1998, AMERICAN CHEMICAL SOCIETY., US, pages 3467 - 3476, XP002194391, ISSN: 0022-2623 *
SUVIT THAISRIVONGS ET AL.: "Structure-based design of Hiv protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, no. 23, 1996, AMERICAN CHEMICAL SOCIETY., US, pages 4630 - 4642, XP002194392, ISSN: 0022-2623 *
ZE-QI XU ET AL.: "In Vitro Anti-Human Immunodeficiency Virus Activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, no. 8, 1998, OXFORD, GB, pages 2179 - 2184, XP004137242, ISSN: 0960-894X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093389B2 (en) 2007-01-12 2012-01-10 Merck Sharp & Dohme Corp. Substituted spirochromanone derivatives

Also Published As

Publication number Publication date
WO2002020509A2 (de) 2002-03-14
AU2001289831A1 (en) 2002-03-22
US20020082264A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2002020509A3 (de) Arzneimittel gegen virale erkrankungen
ATE269321T1 (de) Arzneimittel gegen virale erkrankungen
PL378354A1 (pl) Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
WO2002057287A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
AU2002364730A1 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
WO2001003681A3 (en) Use of flavones, coumarins and related compounds to treat infections
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2008003149A3 (en) Substituted pteridines for the treatment and prevention of viral infections
WO2007049265A3 (en) Anti mineralocorticoid therapy of infection
WO2005013917A3 (en) Combination therapy for treating alphavirus infection and liver fibrosis
EP1256348A4 (de) Heilmittel gegen hepatitis
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
WO2001012228A3 (en) Compositions for treating viral infections, and methods therefor
AU2003249659A1 (en) Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
WO2003025139A3 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
DE60021413D1 (de) Anti-virale zusammensetzung enthaltend ein palmaria palmata extrakt
EP2071030A3 (de) Oligoribonukleotid- und Peptidnukleinsäure zur Hemmung der Aktivität des Hepatitis-C-Virus
WO2002000613A3 (en) Inhibitors of hepatitis b virus infection
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP